文献速递妇科

组织因子-因子VIIa复合物触发蛋白酶激活受体2依赖的生长因子释放和迁移在卵巢癌中

Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-01-29

该研究探讨组织因子(TF)-因子VIIa-蛋白酶激活受体2(PAR-2)通路在人上皮性卵巢癌(EOC)中的作用。TCGA RNAseq数据显示PAR-2表达高于PAR-1,且远高于PAR-3/4;EOC细胞系微粒相关TF凝血活性较对照细胞系增强4-10倍;FVIIa诱导VEGF-A释放增加2.5-3倍,该效应可被PAR-2拮抗剂ENMD-1068消除;凝血酶诱导的增殖可被PAR-1拮抗剂vorapaxar完全逆转。结论认为TF-FVIIa-PAR-2轴活性增强可能通过PAR-2依赖信号促进EOC进展。

要点

  • EOC数据集中PAR-2 mRNA表达高于PAR-1,且远高于PAR-3/4。
  • EOC细胞系来源微粒相关TF凝血活性较对照细胞系增强4-10倍。
  • FVIIa诱导的VEGF-A释放和趋化迁移可被PAR-2拮抗剂ENMD-1068消除。

核心结论

  • TF-FVIIa-PAR-2轴活性增强可能通过PAR-2依赖信号支持血管生成和侵袭表型,并通过局部凝血酶生成支持PAR-1依赖的增殖,从而促进EOC进展。

研究设计与样本

  • 研究分析EOC数据库的TCGA RNAseq数据中的PAR表达,并在人EOC细胞系(SKOV-3、OVCAR-3和CaOV-3)及对照细胞系中检测TF、PAR-1和PAR-2蛋白表达及微粒相关凝血活性。
  • 使用小分子拮抗剂评估FVIIa诱导的VEGF-A释放(ELISA)和趋化迁移的PAR依赖性,以及凝血酶诱导的细胞增殖的PAR依赖性。

主要发现

  • 多个EOC数据集中相对mRNA表达一致显示PAR-2高于PAR-1,且PAR-1远高于PAR-3/4。
  • 人EOC细胞系裂解物证实表达TF、PAR-1和PAR-2蛋白。
  • 从EOC细胞系分离的微粒显示TF凝血活性较对照细胞系增强4-10倍。
  • FVIIa诱导EOC细胞系VEGF-A释放呈剂量依赖性增加2.5-3倍,该效应被PAR-2拮抗剂ENMD-1068消除。
  • FVIIa处理CaOV-3和OVCAR-3细胞导致趋化迁移增加,该效应被ENMD-1068消除;凝血酶诱导的EOC细胞系增殖呈剂量依赖性,并被PAR-1拮抗剂vorapaxar完全逆转。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Enhanced tissue factor (TF) expression in epithelial ovarian cancer (EOC) is associated with aggressive disease. Our objective was to evaluate the role of the TF-factor VIIa-protease-activated receptor-2 (PAR-2) pathway in human EOC. METHODS: TCGA RNAseq data from EOC databases were analyzed for PAR expression. Cell and microparticle (MP) associated TF protein expression (Western blot) and MP-associated coagulant activity were determined in human EOC (SKOV-3, OVCAR-3 and CaOV-3) and control cell lines. PAR-1 and PAR-2 protein expressions were similarly examined. The PAR dependence of VEGF-A release (ELISA) and chemotactic migration in response to FVIIa and cellular proliferation in response to thrombin was evaluated with small molecule antagonists. RESULTS: Relative mRNA expression consistently demonstrated PAR-2>PAR-1≫PAR-3/4 in multiple EOC datasets. Human EOC cell line lysates confirmed expression of TF, PAR-1 and PAR-2 proteins. MPs isolated from EOC cell lines demonstrated markedly enhanced (4-10 fold) TF coagulant activity relative to control cell lines. FVIIa induced a dose-dependent increase in VEGF-A release (2.5-3 fold) from EOC cell lines that was abrogated by the PAR-2 antagonist ENMD-1068. FVIIa treatment of CaOV-3 and OVCAR-3 cells resulted in increased chemotactic migration that was abolished by ENMD-1068. Thrombin induced dose-dependent EOC cell line proliferation was completely reversed by the PAR-1 antagonist vorapaxar. Small molecule antagonists had no effect on these phenotypes without protease present. CONCLUSIONS: Enhanced activity of the TF-FVIIa-PAR-2 axis may contribute to the EOC progression via PAR-2 dependent signaling that supports an angiogenic and invasive phenotype and local thrombin generation supporting PAR-1 dependent proliferation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chanakira A, Westmark PR, Ong IM, et al. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. Gynecol Oncol. 2017. PMID: 28148395. doi:10.1016/j.ygyno.2017.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。